Are Peptides FDA Approved? What Patients Need to Know

Are peptides FDA approved? Some are, and many of the most talked-about ones are not. A number of peptide medicines, such as semaglutide, tirzepatide, tesamorelin and bremelanotide, are FDA approved for specific conditions, while popular "wellness" peptides like BPC-157, TB-500 and Epitalon have never been approved for any human use.

That distinction matters more than most marketing lets on. "Peptide" describes a chemical structure, a short chain of amino acids. It says nothing about whether a product has been tested, manufactured to drug standards, or reviewed by a regulator. In my practice, the first thing I do when a patient asks about a peptide is sort it into one of three buckets: approved, approved elsewhere, or investigational.

Are Peptides FDA Approved? The Three Categories

1. FDA-approved peptide medicines

These have completed the full drug-approval process for a defined indication, with labeled dosing, known side effects, and manufacturing oversight. Examples include:

• Semaglutide, tirzepatide and liraglutide for type 2 diabetes and chronic weight management (specific products and indications vary).
• Tesamorelin (Egrifta) for reducing excess abdominal fat in people with HIV-associated lipodystrophy.
• Bremelanotide (Vyleesi, also known as PT-141) for premenopausal women with hypoactive sexual desire disorder.
• Elamipretide (Forzinity, SS-31), approved in September 2025 for Barth syndrome only.
• Long-established peptide drugs such as insulin, oxytocin, octreotide and leuprolide.

Approval is always for a specific use. Using an approved drug outside its label ("off-label") is legal for physicians but should be grounded in evidence and individual judgment.

2. Approved in other countries, not in the U.S.

Some peptides have regulatory approval abroad but not from the FDA:

• Thymosin alpha-1 (Zadaxin) is approved in more than 30 countries, not in the U.S.
• Cerebrolysin is approved in roughly 50 countries, not in the U.S.
• Selank and Semax are approved in Russia only.

Foreign approval tells us a regulator somewhere reviewed some data. It does not mean the data meet U.S. standards, and it says nothing about the quality of a product shipped from an unknown supplier.

3. Investigational or unapproved

This is where most "trending" peptides live: BPC-157, TB-500, MOTS-c, Epitalon, KPV, GHK-Cu injectables, Ipamorelin, CJC-1295 and others. Their evidence is usually limited to animal studies, cell studies, or small early human reports. Sermorelin is a special case: it was once FDA approved (as Geref) but was discontinued in 2008 for commercial reasons, not safety findings.

What Changed in 2023–2026

Most investigational peptides reach patients in the U.S. through compounding pharmacies, which is why FDA's compounding lists matter so much.

• 2023: FDA placed many peptides, including BPC-157, TB-500, KPV, Semax, MOTS-c, Epitalon, Ipamorelin, CJC-1295, AOD-9604 and others, in "Category 2" of its 503A bulk-substance list, meaning they raised significant safety concerns and should not be compounded.
• April 15, 2026: FDA removed 12 peptides from Category 2 so its Pharmacy Compounding Advisory Committee (PCAC) could review them. Removal from Category 2 was not permission to compound.
• July 2026: The PCAC voted to recommend BPC-157, TB-500, KPV, Semax, MOTS-c and Epitalon for the 503A bulks list, and voted against DSIP. Others, including LL-37, Dihexa, Melanotan II and injectable GHK-Cu, are scheduled for review before February 2027.
• Earlier votes against included Ipamorelin, MK-677 and Kisspeptin-10 (October 2024) and CJC-1295 and AOD-9604 (December 2024).

Even if a peptide is eventually added to the bulks list, that would allow licensed pharmacies to compound it under a prescription. It would still not make it an FDA-approved drug with proven efficacy for a specific condition. The difference between pharmacy types is explained in the FDA 503A vs 503B pharmacy distinction.

Why "Research Use Only" Is a Red Flag

Many websites sell peptides labeled "for research use only, not for human consumption." That label is a legal disclaimer, not a quality claim. These products:

• Are not made under drug manufacturing standards.
• Have not been verified for identity, purity, sterility or endotoxin.
• Shift all responsibility to the buyer.

I never recommend buying research peptides or self-injecting. The reasons are laid out in why self-injecting research peptides can be risky.

How to Read Peptide Claims as a Patient

When you see a peptide promoted online, a few questions cut through the noise:

1. Is it FDA approved, and for what? If not, the evidence is probably early.
2. What kind of evidence is cited? Mouse studies and cell cultures generate hypotheses. They do not establish that something works or is safe in people.
3. Who makes it? A licensed U.S. pharmacy filling a prescription is very different from an overseas website.
4. Who is monitoring you? Any therapy that affects hormones, growth signaling or blood vessels deserves baseline and follow-up labs.

How I Approach Peptides at Laeeq M.D.

At Laeeq M.D., peptide conversations start with internal medicine: a full history, a medication review and labs. Often the most useful finding is something conventional, such as an under-active thyroid, iron deficiency, poor sleep or early insulin resistance, that has a well-proven treatment.

When a peptide is reasonable to discuss, I explain its regulatory status honestly and say plainly what is proven, what is promising, and what is unknown. FDA-approved options come first when they fit. Dosing for anything investigational is individualized and only discussed after evaluation and labs. You can browse the evidence summaries in our peptide library before your visit.

Sources

• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
• Bulk-list bound? PCAC backs majority of peptides in two-day public meeting — McDermott Will & Schulte, 2026. https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/
• FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides — Goodwin Procter, 2026. https://www.goodwinlaw.com/en/insights/blogs/2026/05/fda-signals-potentially-evolving-stance-toward-compounding-of-certain-peptides

Book a Consultation

If you are weighing a peptide and want a clear, honest read on its regulatory status and evidence, start with a full medical evaluation. You can book a consultation for a 60-minute visit with Dr. Laeeq, virtually or in person in Reston, VA, for patients in Virginia, Maryland, Florida, Texas, California, Pennsylvania and Tennessee.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.